Drug intelligence / Profile preview

5-fluorouracil + capecitabine + cyclophosphamide + docetaxel + epirubicin

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination of five chemotherapeutic agents used in cancer treatment. 5-fluorouracil (5-FU) and capecitabine are fluoropyrimidine antimetabolites that interfere with DNA synthesis. Capecitabine is a prodrug that is converted to 5-FU predominantly in tumor tissue. Cyclophosphamide is an alkylating agent, docetaxel is a taxane that disrupts microtubule function, and epirubicin is an anthracycline antibiotic that intercalates with DNA. This combination may be used in advanced breast cancer or other solid tumors, though it is not a standard regimen mentioned in the literature.

Targets

DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on 5-fluorouracil + capecitabine + cyclophosphamide + docetaxel + epirubicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-fluorouracil + capecitabine + cyclophosphamide + docetaxel + epirubicin.

Explore the full profile